# MCE MedChemExpress

## **Product** Data Sheet

### **Elinzanetant**

 Cat. No.:
 HY-109171 

 CAS No.:
 929046-33-3 

 Molecular Formula:
  $C_{33}H_{35}F_{7}N_{4}O_{3}$  

 Molecular Weight:
 668.64 

Target: Neurokinin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (149.56 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.4956 mL	7.4779 mL	14.9557 mL
	5 mM	0.2991 mL	1.4956 mL	2.9911 mL
	10 mM	0.1496 mL	0.7478 mL	1.4956 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.74 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.74 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description

Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can be used in vasomotor and schizophrenia studies  $^{[1][2]}$ .

#### **REFERENCES**

[1]. Simon JA, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3):239-246.

21. Alvaro, Giuseppe: Andreott	i. Daniele: Belvedere. Sand	Iro: Di Fabio. Romano: Falchi. Ales	sandro; Giovannini, Riccardo.Pyridine de	rivatives as NK receptor inhibitors and
		e in the treatment of psychotic dis		
e proparation, priamiaceae	rear compositions, and acc	and the discussion of poyenous and	0.40.0.0.11010000111	
	Caution: Product has	not been fully validated for n	nedical applications. For research us	e only.
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpre	ss com
				33.0011
	Address	: 1 Deer Park Dr, Suite Q, Monn	nouth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com